<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641599</url>
  </required_header>
  <id_info>
    <org_study_id>RV</org_study_id>
    <nct_id>NCT03641599</nct_id>
  </id_info>
  <brief_title>Right Ventricular Function in Heart Failure</brief_title>
  <official_title>Assessment Right Ventricular Systolic Function in Heart Failure With Preserved, Reduced and Mid-range Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>shaimaa Mostafa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Only a few studies evaluated the RV systolic function in the three categories of HF,
      regarding the importance of understanding changes in RV function on clinical presentation and
      outcome; it was essential to understand the prevalence and severity of RV dysfunction among
      the three groups and the degree of correlation between RV with LV systolic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of the RV systolic dysfunction in patients with heart failure</measure>
    <time_frame>1.5 year</time_frame>
    <description>degree and prevalence of the RV systolic dysfunction in patients with heart failure with preserved, mid-range and decreased ejection fraction</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Assessment of the RV Function in Patients With Heart Faliure</condition>
  <arm_group>
    <arm_group_label>heart failure with preserved ejection fraction</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>heart failure with mid range ejection fraction</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>heart failure with reduced ejection fraction</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>echocardiography</intervention_name>
    <description>echocardiographic assessment of the RV and LV systolic function</description>
    <arm_group_label>heart failure with mid range ejection fraction</arm_group_label>
    <arm_group_label>heart failure with preserved ejection fraction</arm_group_label>
    <arm_group_label>heart failure with reduced ejection fraction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HFpEF&gt;50%, HFrEF&lt;40% and HFmrEF &gt;40% and &lt;50%
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Adult patients of both gender who have the followiong criteria :

        (i) symptoms with or without signs of HF (ii) elevated natriuretic peptides (BNP ≥35pg/ mL
        or NT-proBNP≥125pg/mL) (iii) relevant structural heart disease: left ventricle hypertrophy
        (left ventricular mass index ≥115 g/m2 for males and ≥95 g/m2 for females) or left atrial
        enlargement (&gt;34 mL/m2) or diastolic dysfunction (E/e'≥13 and a mean e' septal and lateral
        wall &lt;9 cm/s) were included.

        Then patients were classified according to EF into HFpEF&gt;50%, HFrEF&lt;40% and HFmrEF &gt;40% and
        &lt;50%

        Exclusion Criteria:

        Patients with chronic obstructive pulmonary disease history of pulmonary embolism patients
        with respiratory failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>shaimaa Mostafa</investigator_full_name>
    <investigator_title>assistant professor of cardiovascular medicicne</investigator_title>
  </responsible_party>
  <keyword>RV systolic function</keyword>
  <keyword>HFpEF</keyword>
  <keyword>HFmrEF</keyword>
  <keyword>HFrEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

